SS Innovations International (NASDAQ: SSII) announced record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year, driven by a 30.4% rise in installations of its SSi Mantra surgical robotic system to 30 units. The company's gross profit climbed 20% to $7.1 million, with a gross margin of 50.9%, reflecting improved operational efficiency. Despite a net loss of $2.7 million, or $0.01 per diluted share, compared to a $0.3 million loss a year earlier, the company's strategic investments in expansion and regulatory approvals are positioning it for long-term growth.
For the first half of 2026, revenue surged 65.6% to $25 million, while SSi Mantra installations rose 47.4% to 56 systems. As of June 30, SS Innovations had $13.6 million in cash and cash equivalents, no long-term debt, and a cumulative installed base of 224 SSi Mantra systems across 12 countries. The company also reported 12,272 cumulative procedures performed using the SSi Mantra, including 175 telesurgeries. Notably, it recently completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, demonstrating the system's capability to enable remote surgical procedures across vast distances.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the company's 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027. The company also believes it can obtain European Union CE marking certification by the end of 2026. These regulatory milestones are critical for expanding into major markets, as they would allow the company to commercialize its technology in the United States and Europe, potentially unlocking significant revenue opportunities.
The strong revenue growth and expanding installed base highlight the increasing adoption of the SSi Mantra, which is designed to make robotic surgery affordable and accessible to a larger segment of the global population. By offering a cost-effective and user-friendly alternative to existing systems, SS Innovations is addressing a critical gap in healthcare technology, particularly in emerging markets where robotic surgery has been historically underutilized.
The company's focus on telesurgery also positions it at the forefront of a transformative trend in healthcare, enabling surgeons to perform procedures remotely and expanding access to specialized care. The successful long-distance telesurgery between Colombia and India is a testament to the reliability and potential of the SSi Mantra system.
With a solid cash position, no long-term debt, and a growing pipeline of installations, SS Innovations is well-positioned to continue its expansion. The expected regulatory approvals in the coming years could serve as catalysts for further growth, allowing the company to penetrate new markets and solidify its presence globally. As the demand for minimally invasive surgical options rises, SS Innovations' innovative approach and strategic execution will be key to capitalizing on this opportunity.
For more information, visit the company's newsroom at https://ibn.fm/SSII.
